ALAMEDA, Calif.--(BUSINESS WIRE)--
InSite Vision Incorporated (INSV) announced today that it will report financial results for the first quarter ended March 31, 2013 on Tuesday, May 7, 2013.
Company management will host a conference call that day beginning at 4:30 p.m. ET/1:30 p.m. PT to discuss first quarter 2013 financial results and to review recent accomplishments and upcoming milestones. Investors will be invited to ask questions following management’s prepared remarks.
Analysts and investors can participate in the conference call by dialing 888-713-4205 for domestic callers and 617-213-4862 for international callers using the pass code 64513927. The live conference call will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. Please join the call at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PKTTH6BJN. A telephone replay will be available following the conclusion of the call by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers using the pass code 55617625.
A press release detailing first quarter 2013 financial results will be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K.
About InSite Vision
InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.
The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision is also advancing three novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus™ and DexaSite™ for the treatment of eye infections, and BromSite™ for pain and inflammation associated with ocular surgery. For further information on InSite Vision, please visit www.insitevision.com.
AzaSite® and DuraSite® are registered trademarks
of InSite Vision Incorporated.
AzaSite Plus™, BromSite™ and DexaSite™ are trademarks of InSite Vision Incorporated.
BESIVANCE® is a registered trademark of Bausch + Lomb Incorporated.
- Health Care Industry
Louis Drapeau, 510-747-1220
Chief Financial Officer
Media and Investor inquiries:
Michelle Corral, 415-794-8662
Karen L. Bergman, 650-575-1509